Provencio M, Majem M, Guirado M, et al. - Researchers assessed progression-free survival (PFS) among 65 treatment-naïve non-small cell lung cancer patients with unresectable stage III disease, who were managed with 2 cycles of induction cisplatin at 80 mg/m² every 21 days plus metronomic oral vinorelbine at 50 mg/day every Monday, Wednesday and Friday. During the concomitant management with thoracic radiotherapy cisplatin was given in the same manner but oral vinorelbine was lowered to 30 mg/day. The goal was to deliver a total radiotherapy dose of 66 Gy in 33 daily fractions of 2 Gy. The overall response rate was estimated to be 66.2%, as assessed using RECIST (Response Evaluation Criteria In Solid Tumors) criteria. A median PFS of 11.5 months was reported. In the intention-to-treat group, PFS at 12 months was noted to be 47.8% and median overall survival was identified to be 35.6 months. Findings of this open-label, single-arm, phase II trial revealed that metronomic oral vinorelbine and cisplatin conferred similar effectiveness with significantly lower toxicity vs the same chemotherapy at standard doses. Groups with particularly good prognosis can be detected by circulating tumor DNA.